Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBGHTW)

• Drug Name: CCNCSSKWCRDHSRCC Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 91935560
  TTD Drug ID: DMBGHTW

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[2]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[3]
V-102862	DMR2EUV	N. A.	N. A.	Discontinued in Phase 1	[4]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[5]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[5]
BW-202W92	DMFKXMT	Discovery agent	N.A.	Investigative	[3]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[1]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[1]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[1]
ZNCCNCSSKWCRDHSRCC	DMY2V37	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[7]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[7]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[7]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[7]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[7]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[8]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[9]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[6]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Inhibitor	[1]

References

• [1] Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
• [2] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [3] Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
• [4] 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
• [5] Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
• [6] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [7] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [8] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [9] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).